Showing 1561-1570 of 1673 results for "".
- Restylane® Refyne and Restylane® Defyne Show Lasting Natural Benefit in Phase 4 Studieshttps://modernaesthetics.com/news/restylane-refyne-and-restylane-defyne-show-lasting-natural-benefit-in-phase-4-studies/2472251/Two Phase 4 clinical studies of Restylane® Refyne and Restylane® Defyne show that the natural-looking results last. Specifically, the Natural Expression study found that naturalness in facial expressions was at least main
- Galderma Rolls Out Restylane Refyne, Defynehttps://modernaesthetics.com/news/galderma-rolls-out-restylane-refyne-defyne/2472262/With a growing number of hyaluronic acid (HA) fillers available and even more in the pike, Galderma is highlighting how their two newest fillers --
- Galderma, Colorescience to Collaborate on Innovative Skincarehttps://modernaesthetics.com/news/galderma-colorescience-to-collaborate-on-innovative-skincare/2472266/Galderma will collaborate with Colorescience to expand skincare solutions to individuals who seek innovative daily skincare products that can be used in conjunction with traditional facial injectable aesthetic treatments, the companies have announced. Galderma and
- Cynosure to Be Acquired by Hologichttps://modernaesthetics.com/news/cynosure-to-be-acquired-by-hologic/2472278/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion
- In a Week of Surprising Acquisitions, Will Syneron Be Next?https://modernaesthetics.com/news/in-a-week-of-surprising-acquisitions-will-syneron-be-next/2472276/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan
- Allergan Agrees to Acquire ZELTIQ for $2.47 Billionhttps://modernaesthetics.com/news/allergan-agrees-to-acquire-zeltiq-for-247-billion/2472280/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- Happy 10th Birthday Radiesse!https://modernaesthetics.com/news/happy-10th-birthday-radiesse/2472291/Merz Aesthetics’ flagship brand, Radiesse, turned 10 this year, and was feted in style at a throw-back Thursday media event in New York City. The party took beauty bloggers and journos back to 2007 when the first iPhone was releas
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Recently Retired American Academy of Facial Plastic and Reconstructive Surgery CEO Receives AMA Lifetime Achievement Awardhttps://modernaesthetics.com/news/recently-retired-american-academy-of-facial-plastic-and-reconstructive-surgery-ceo-receives-ama-lifetime-achievement-award/2472317/The American Medical Association (AMA) has presented the Medical Executive Lifetime Achievement Award to Stephen C. Duffy, former executive vice president and CEO of the American Academy of Facial Plastic and Reconstructive Sur